S-100B and FDG-PET/CT in therapy response assessment of melanoma patients

Dermatology

Volumn 215, Issue 3, 2007, Pages 192-201

  Strobel, Klaus ^a   Skalsky, Jeannine ^b   Steinert, Hans C ^a   Dummer, Reinhard ^b   Hany, Thomas F ^a   Bhure, Ujwal ^a   Seifert, Burkhardt ^c   Pérez Lago, Marisol ^a   Joller Jemelka, Helen ^a   Kalff, V ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Melanoma; Positron emission tomography; S 100B protein

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN S100B;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SKIN METASTASIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NERVE GROWTH FACTORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; S100 PROTEINS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 34548495285     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106575     Document Type: Article

References (29)

1. Hansson LO, von Schoultz E, Djureen E, Hansson J, Nilsson B, Ringborg U: Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res 1997;17:3071-3073.
2. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A, Atzpodien J: Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997;75:1373-1376.
3. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA: Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997;137:381-385.
4. Schultz ES, Diepgen TL, Von Den Driesch P: Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998;138:426-430.
5. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G: Serum S100 - A marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208-212.
6. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999;56:338-344.
7. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-1071.
8. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999;9:155-161.
9. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R: Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006;213:187-191.
10. 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-1187.
11. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-1327.
12. Jerusalem G, Hustinx R, Beguin Y, Fillet G: Evaluation of therapy for lymphoma. Semin Nucl Med 2005;35:186-196.
13. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-4698.
14. Ott K, Weber W, Siewert JR: The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006;19:433-442.
15. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-8370.
16. 18F-FDG PET. J Nucl Med 2005;46:1144-1150.
17. Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, Song SY: The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40:923-929.
18. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-365.
19. 18F]-2-fluoro-2-deoxyglucose (PET-FDG) modeled in metastatic renal cell cancer. Clin Positron Imag 2000;3:57-65.
20. 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-895.
21. Eigentler TK, Caroli UM, Radny P, Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759.
22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
23. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745.
24. Munden RF, Macapinlac HA, Erasmus JJ: Esophageal cancer: the role of integrated CTPET in initial staging and response assessment after preoperative therapy. J Thorac Imag 2006;21:137-145.
25. Weber WA: Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-995.
26. Ryan ER, Hill AD, Skehan SJ: FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med 2006;31:707-708.
27. Reinhardt MJ, Kensy J, Frohmann JP, Willkomm P, Reinhold U, Grunwald F, Biersack HJ, Bender H: Value of tumour marker S-100B in melanoma patients: a comparison to 18 F-FDG PET and clinical data. Nuklearmedizin 2002;41:143-147.
28. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R: Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imag 1999;2:159-171.
29. Sze G, Shin J, Krol G, Johnson C, Liu D, Deck MD: Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology 1988;168:187-194.